> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # Roivant Sciences - URL: https://www.whiteroseintelligence.com/roivant-sciences/ - Published: 1999-01-02T23:31:00.000Z - Updated: 2025-01-03T22:51:06.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, #organization **Roivant Sciences** is an American-Swiss pharmaceutical and biotechnology company based in New York City, with offices in Boston, Massachusetts and Basel, Switzerland. It was founded by [Vivek Ramaswamy](https://www.whiteroseintelligence.com/Vivek-Ramaswamy) in 2014.[\[1\]](#fn1) ## History Ramaswamy incorporated the company on April 7, 2014 in Bermuda.[\[2\]](#fn2)[\[3\]](#fn3) On September 20, 2017, Roivant announced the launch of [Datavant](https://www.whiteroseintelligence.com/Datavant), "a new company focused on employing artificial intelligence to improve the clinical trial process."[\[4\]](#fn4) Travis May and Sam Roosz are credited as co-founders.[\[5\]](#fn5) In April 2018, Roivant announced that it was joining forces with [Arbutus Biopharma](https://www.whiteroseintelligence.com/Arbutus-Biopharma) to launch Genevant Sciences, a jointly-owned venture focused on “the discovery, development, and commercialization of a broad range of RNA-based therapeutics” aiming for “5-10 product candidates into the clinic by 2020.”[\[6\]](#fn6) ### COVID-19 On February 26, 2021, Roivant announced its acquisition of Silicon Therapeutics.[\[7\]](#fn7) ## Organization Roivant is a member company of the Biotechnology Innovation Organization (BIO).[\[8\]](#fn8) ### Personnel | Name | Position | Notes | | ------------------------------------------------------------------------ | -------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------- | | [Vivek Ramaswamy](https://www.whiteroseintelligence.com/Vivek-Ramaswamy) | Founder[\[2:1\]](#fn2) | [Strive Asset Management](https://www.whiteroseintelligence.com/Strive-Asset-Management), Campus Venture Network | | Jo Chen | General Counsel[\[9\]](#fn9) | JHL Capital Group, Bain Capital, D. E. Shaw & Co., Weil, Gotshal & Manges | | Alex Gasner | Executive Vice President | Bee | | Matt Gline | Chief Executive Officer | Goldman Sachs, Fourthree, Barclays | | Kelly Graff | Head of People | Interferometrics, Delta Analysis Group, Entegra Systems, Stevenson Search Partners, Occam Global, American Cancer Society (ACS) | | Drew Krames | Chief Information Officer | Pivotal, VMWare, OneCloud | | Rakhi Kumar | Chief Accounting Officer | The Medicines Company, Ernst & Young, NeuroPace | | Amy Mahery | Chief Commercial Officer | EMD Serono | | Matt Maisak | Chief Operating Officer | Axovant Sciences, Covant Therapeutics, Roche, Projects Abroad | | Richard Pulik | Chief Financial Officer | Novartis, Merrill Lynch, UBS Investment Bank, Monitor Group, William Alanson White Institute | | Srini Ramanathan | Chief Development Officer | Horizon Therapeutics, AbbVie, Gilead Sciences, Asian University for Women (AUW) | | Mayukh Sukhatme | President and Chief Investment Officer | Narragansett Asset Management, Apothecary Capital, Sigma Capital, Sio Capital Management, Hutchin Hill Capital, Apple Tree Partners (ATP) | | Frank Torti | Vant Chair | Telavant, Immunovant, [New Enterprise Associates](https://www.whiteroseintelligence.com/New-Enterprise-Associates) (NEA) | | Eric Venker | President and Chief Operating Officer | NewYork-Presbyterian Hospital, Yale New Haven Hospital | ### Investors Investors in Roivant include:[\[10\]](#fn10)[\[11\]](#fn11)[\[12\]](#fn12) - Dexcel Pharma - Eventide - Fidelity Investments - [Founders Fund](https://www.whiteroseintelligence.com/Founders-Fund) - NovaQuest Capital Management - [Palantir Technologies](https://www.whiteroseintelligence.com/Palantir-Technologies) - Patient Square Capital - QVT Financial - RTW Investments - SoftBank Vision Fund[\[13\]](#fn13) - Sumitomo Pharma - Suvretta Capital Management - Viking Global Investors ### Portfolio Companies in Roivant's portfolio include:[\[10:1\]](#fn10)[\[14\]](#fn14)[\[15\]](#fn15) - Affivant Sciences - [Arbutus Biopharma](https://www.whiteroseintelligence.com/Arbutus-Biopharma)[\[16\]](#fn16) - Axovant Sciences - Covant Therapeutics - [Datavant](https://www.whiteroseintelligence.com/Datavant) - Dermavant Sciences - Enzyvant[\[4:1\]](#fn4) - Gen-t Science - Genevant Sciences - Hemavant Sciences - Immunovant - Kinevant - Lokavant - Medallion - Myovant Sciences[\[4:2\]](#fn4) - Priovant Therapeutics - Proteovant Therapeutics - Psivant Therapeutics - Silicon Therapeutics[\[7:1\]](#fn7) - Telavant - Urovant[\[4:3\]](#fn4) - VantAI ## Activities Roivant has provided notable funding to: - [Alliance for Aging Research](https://www.whiteroseintelligence.com/Alliance-for-Aging-Research)[\[17\]](#fn17) - Bipartisan Policy Center (BPC)[\[18\]](#fn18) ## External links - [Crunchbase](https://www.crunchbase.com/organization/roivant-sciences) - [LinkedIn](https://www.linkedin.com/company/roivant-sciences-inc-/?originalSubdomain=ch) - [Website](https://www.roivant.com/) --- 1. *Company Overview.* Roivant. Retrieved May 27, 2024, from [↩︎](#fnref1) 2. Lee, S. (2023, February 21). *Roivant Sciences Announces Change to its Board of Directors.* Roivant Sciences. [↩︎](#fnref2) [↩︎](#fnref2:1) 3. Bermuda Registrar of Companies. (2017, January 10). *Roivant Sciences Ltd.* OpenCorporates. [↩︎](#fnref3) 4. Davis, P., & Roosz, S. (2017, September 20). *Roivant Sciences Launches Datavant to Improve Clinical Trials with Artificial Intelligence*. Roivant Sciences. [↩︎](#fnref4) [↩︎](#fnref4:1) [↩︎](#fnref4:2) [↩︎](#fnref4:3) 5. *Sam Roosz.* Federation of American Scientists. Retrieved December 7, 2023, from [↩︎](#fnref5) 6. Tolmie, T., & Schull, D. (2018, April 11). *Arbutus and Roivant Launch Genevant Sciences with Industry-Leading Platform to Develop Broad Range of RNA Therapeutics for Genetic Diseases.* Arbutus Biopharma. [↩︎](#fnref6) 7. Landenberger, L. (2021, February 26). *Roivant acquires Silicon Therapeutics for $450M in equity.* BioWorld. [↩︎](#fnref7) [↩︎](#fnref7:1) 8. *BIO Member Directory.* Biotechnology Innovation Organization. Retrieved September 30, 2022, from [↩︎](#fnref8) 9. *Leadership.* Roivant. Retrieved May 27, 2024, from [↩︎](#fnref9) 10. *Roivant Sciences - Financials.* Crunchbase. Retrieved May 27, 2024, from [↩︎](#fnref10) [↩︎](#fnref10:1) 11. *Private Equity Round - Roivant Sciences.* Crunchbase. Retrieved May 27, 2024, from [↩︎](#fnref11) 12. *Company Overview.* Roivant. Retrieved May 27, 2024, from [↩︎](#fnref12) 13. *Portfolio*. SoftBank Vision Fund. Retrieved May 5, 2023, from [↩︎](#fnref13) 14. *Our Companies.* Roivant. Retrieved May 27, 2024, from [↩︎](#fnref14) 15. *Our Companies.* Roivant. Retrieved August 15, 2022, from [↩︎](#fnref15) 16. *Arbutus Biopharma - Funding, Financials, Valuation & Investors.* Crunchbase. Retrieved August 25, 2023, from [↩︎](#fnref16) 17. *How We’re Funded.* Alliance for Aging Research. Retrieved August 6, 2020, from [↩︎](#fnref17) 18. *Annual Report 2018.* (2018). Bipartisan Policy Center. [↩︎](#fnref18)